China
Ascentage Pharma is a global, clinical-stage biotechnology company established in 2009 and headquartered in China. The company focuses on developing innovative therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.
Their dedication lies in developing and bringing to market therapies that target each class of molecular pathways regulating apoptosis, or programmed cell death, in a wide range of indications. Ascentage Pharma has built a pipeline of seven clinical drug candidates, including novel, highly selective and potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, additional apoptotis inhibitors targeting IAP and MDM2-p53 proteins. The pipeline is balanced by next-generation tyrosine kinase inhibitors (TKIs) aimed at treatment-induced resistance mutations. Currently, the company is conducting more than 40 clinical trials in specific regions worldwide.
In their most recent milestone, Ascentage Pharma secured a $75.00M post-IPO equity investment at 20 June 2024, with Takeda as the investor. This investment further validates the company's potential and highlights the confidence major players in the industry have in their innovative approaches.
With a growing global presence and a robust pipeline, Ascentage Pharma is poised to make significant strides in addressing unmet medical needs across various therapeutic areas.
GLG Pharma
